<DOC>
	<DOCNO>NCT01262352</DOCNO>
	<brief_summary>The purpose study evaluate effect ivacaftor ( VX-770 ) lung clearance index ( LCI ) subject age 6 year older cystic fibrosis ( CF ) G551D-CFTR mutation least 1 allele .</brief_summary>
	<brief_title>Study Effect Ivacaftor Lung Clearance Index Subjects With Cystic Fibrosis G551D Mutation</brief_title>
	<detailed_description>Currently , limit objective measure available quantify lung function CF patient mild lung disease . Lung clearance index ( LCI ) derive inert gas multiple-breath washout ( MBW ) test hold considerable promise evaluate early lung disease study detect abnormality high percentage CF patient normal spirometry infant child . This study explore effect ivacaftor LCI efficacy ivacaftor clinical biomarker endpoint CF lung disease subject age 6 year old CF G551D-CFTR mutation least 1 allele .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female subject confirm diagnosis CF Must G551DCFTR mutation least 1 allele FEV1 &gt; 90 % predict normal age , gender , height Ongoing participation another therapeutic clinical study prior participation investigational drug study within 30 day prior screen Use inhale hypertonic saline treatment within 2 week Period 1 , Day 1 visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>